The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 21, 2020

Filed:

Dec. 09, 2016
Applicant:

Expression Pathology, Inc., Rockville, MD (US);

Inventors:

Adele Blackler, Rockville, MD (US);

Todd Hembrough, Gaithersburg, MD (US);

Fabiola Cecchi, Rockville, MD (US);

Paolo Nuciforo, Barcelona, ES;

Assignee:

Expression Pathology, Inc., Rockville, MD (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/517 (2006.01); G01N 33/574 (2006.01); G01N 33/68 (2006.01); G01N 30/72 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/517 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); G01N 33/57415 (2013.01); G01N 33/6848 (2013.01); G01N 2333/91205 (2013.01); G01N 2560/00 (2013.01);
Abstract

Methods of treating breast cancer are provided where a quantitative Her2 assay is used to identify whether a breast tumor will be responsive to treatment with anti-Her2 therapeutic agents such as lapatinib and trastuzumab, followed by selection of a suitable treatment regimen and administration of the regimen. A specific Her2 fragment peptide is precisely quantitated by SRM-mass spectrometry directly in breast tumor cells collected from breast tumor tissue that was obtained from a cancer patient and compared to a reference level in order to determine if the breast cancer patient will positively respond to treatment with a therapeutic agent that specifically targets the Her2 protein.


Find Patent Forward Citations

Loading…